SavedAdd your journal

Journals / Hacettepe Journal of Biology and Chemistry / 2017 / Cilt: 45 - Sayı: 2

Inhibiting Downstream Signaling Pathway of FIT3 in Acute Myeloid Leukemia

Akut Myeloid Lösemide FLT3 Sinyalizasyon Yolakının Akış Yönünde İnhibisyonu

Mynyr KONI
Gledjan CAKA
Pages
257–262
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We used specific target inhibitors to elucidate the combined effects of NOX4 inhibition and the inhibition of FLT3-ITD tyrosine kinase on FLT3-ITD signal transduction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:FLT3 is a type 3 tyrosine kinase receptor susceptible to different genetic mutations in acute myeloid leukemia.
📊
Key Findings & Data:Several studies have shown that a large number of patients (approximately one third) have mutations of this gene, lead of which is internal tandem duplications (ITD) that leads to activation of downstream signaling pathway and abnormal cellular growth.
💡
Conclusion & Impact:We used specific target inhibitors to elucidate the combined effects of NOX4 inhibition and the inhibition of FLT3-ITD tyrosine kinase on FLT3-ITD signal transduction.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

FLT3 is a type 3 tyrosine kinase receptor susceptible to different genetic mutations in acute myeloid leukemia. Several studies have shown that a large number of patients (approximately one third) have mutations of this gene, lead of which is internal tandem duplications (ITD) that leads to activation of downstream signaling pathway and abnormal cellular growth. We used specific target inhibitors to elucidate the combined effects of NOX4 inhibition and the inhibition of FLT3-ITD tyrosine kinase on FLT3-ITD signal transduction.

Özet

FLT3 akut miyeloid lösemide farklı genetik mutasyonlara duyarlı tip 3 tirozin kinaz reseptörüdür. Birçok çalışma, çok sayıda hastada (yaklaşık üçte biri) bu genin mutasyona uğradığını göstermiştir; bunun nedeni aşağı akış sinyal yolağı ve anormal hücre çoğalmasının yol açtığı iç tandem duplikasyonlardır (ITD). Bu çalışmada, NOX4 inhibisyonunun kombine etkilerini ve FLT3-ITD sinyal iletiminde FLT3-ITD tirozin kinazın inhibisyonunu aydınlatmak için özgül hedef inhibitörleri kullanılmıştır.

🔖

Cite This Article

KONI, M., CAKA, G. (2022). Inhibiting Downstream Signaling Pathway of FIT3 in Acute Myeloid Leukemia. Hacettepe Journal of Biology and Chemistry, Cilt: 45 - Sayı: 2, 257–262. https://ajindex.com/articles/529117

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. J.E. Darnell, I.M. Kerr, G.R. Stark, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins, Science, 264 (1994) 1415–1420.
  2. M. Levis, K.F. Tse, B.D. Smith, E. Garrett, D.A. Small, A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations, Blood, 98 (2001) 885–887.
  3. S. Yokota, H. Kiyoi, M. Nakao, T. Iwai, S. Misawa, T. Okuda, Y. Sonoda, T. Abe, K. Kahsima, Y. Matsuo, T. Naoe, Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines, Leukemia, 11 (1997) 1605– 1609. M. Levis, K.F. Tse, B.D. Smith, E. Garrett, D.A. Small, FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations, Blood, 98 (2001) 885-88.
  4. M. Levis, J. Allebach, K.F. Tse, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo, Blood, 99 (2002) 3885-3891.
  5. K.F. Tse, J. Allebach, M. Levis, Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor, Leukemia, 16 (2002) 2027-2036.
  6. S. Meshinchi, W.G. Woods, D.L. Stirewalt, Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia, Blood, 97 (2001) 89-94.
  7. H. Kiyoi, T. Naoe, Y. Nakano, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93 (1999) 3074-3080.
  8. P.D. Kottaridis, R.E. Gale, M.E. Frew, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, Blood, 98 (2001) 1752-1759.
  9. R.M. Stone, T. Fischer, R. Paquette, G. Schiller, C.A. Schiffer, G. Ehninger, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia, Leukemia, 26 (2012) 2061–2068.
  10. C.C. Smith, Q. Wang, C.S. Chin, S. Salerno, L.E. Damon, M.J. Levis, Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia, Nature, 485 (2012) 260–263.
  11. V. Calo, M. Mig